Danaher Corp

NYSE:DHR

Earnings Call Analysis

Danaher Reports Strong Q3 2024, Offers Cautious Outlook for Growth

In Q3 2024, Danaher's revenue reached $5.8 billion with a 0.5% core growth. Significant gains were noted in bioprocessing, while Diagnostics surged with double-digit growth at Cepheid. Despite an expected decline in overall core revenue for the year, guidance remains stable, predicting a low single-digit decline. Operating margins are projected to be around 30% for Q4. Challenges persist in China with mid-single-digit revenue drop and slowed order intensity, but a gradual recovery is anticipated. Danaher remains optimistic about long-term growth, driven by innovations in life sciences and diagnostics.

A Strong Third Quarter Performance

Danaher Corporation reported impressive third-quarter results for 2024, with total sales reaching $5.8 billion. This figure marks a 0.5% increase in core revenue, primarily driven by slight growth in developed markets, particularly in North America and Western Europe. Notably, the company generated $1.2 billion in free cash flow during the quarter, further underlining its robust financial health.

Segment Highlights and Challenges

In the Biotechnology segment, overall performance was steady, with core revenues flat year-over-year. However, there was positive growth in the bioprocessing business, while the Discovery and Medical businesses faced higher declines. The Diagnostics segment, on the other hand, experienced a 5% increase in core revenue, with Cepheid notably achieving double-digit growth. Yet, high-growth markets like China showed a mid-single-digit decline, reflecting ongoing challenges in capital expenditure among domestic customers.

Investment in Innovations

Danaher continues to invest in innovation, with several product launches aimed at enhancing its competitive edge. The introduction of the Cydem VT, a high-throughput cell culture system, is expected to significantly reduce workflow times, improving the viability of research initiatives. Furthermore, the acquisition of Genedata will bolster the company's capabilities in streamlining drug discovery processes, indicating a strategic focus on enhancing efficiency and productivity across its biotech portfolio.

Future Outlook and Guidance

Looking ahead, Danaher maintains a cautiously optimistic outlook for the remainder of 2024 and into next year. For Q4, the company anticipates core revenue declines in the low single-digit percentage range, alongside an adjusted operating profit margin projected at approximately 30%. For the full year, a core revenue decline is expected in the low single digits, with a total adjusted operating profit margin of around 29%. Additionally, there is hope for a rebound in bioprocessing orders, supported by a solid backlog, as the company enters 2025 with a projected gradual recovery.

Market Dynamics and Regional Performance

The company has observed varying dynamics across different geographic regions. In developed markets, early signs of demand recovery among pharmaceutical customers provide a positive outlook. In China, however, customer purchasing decisions remain uncertain, influenced by a lack of concrete details surrounding governmental stimulus measures. As a result, the expected recovery in orders from smaller biopharma customers remains muted compared to their larger counterparts.

Investment Strategy and M&A Activity

Danaher remains active in its pursuit of mergers and acquisitions to strengthen its market position. While eager to explore opportunities, the company emphasizes a disciplined approach due to elevated valuations in the current market landscape. This strategic focus highlights Danaher's commitment to building a robust portfolio that aligns with its high-growth and high-impact business model.

Conclusion: A Compelling Long-term Investment

As Danaher continues to navigate complex market challenges while maintaining robust financial performance, its commitment to innovation and strategic investments positions the company favorably for future growth. With a solid foundation and execution of the Danaher Business System, the company is well poised to drive long-term value for its shareholders.

Earnings Call Transcript 2024-Q3

[Operator]

My name is Ashley, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to the Danaher Corporation's Third Quarter 2024 Earnings Results Conference Call. [Operator Instructions]

I will now turn the call over to Mr. John Bedford, Vice President of Investor Relations. Mr. Bedford, you may begin your conference.

[John Bedford, executive]

Good morning, everyone, and thanks for joining us on the call. With us today are Rainer Blair, our President and Chief Executive Officer; and Matt McGrew, our Executive Vice President and Chief Financial Officer.

I'd like to point out that our earnings release, Form 10-Q, the slide presentation supplementing today's call, the reconciliations and other information required by SEC Regulation G relating to the non-GAAP financial measures we'll be discussing during the call, and a note containing details of historical and anticipated future financial performance are all available on the Investors section of our website, www.danaher.com under the heading Quarterly Earnings.

The audio portion of this call will be archived on the Investors section of our website later today. under the heading Events and Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until November 5, 2024.

During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to results from continuing operations, and relate to the third quarter of 2024, and all references to period-to-period increases or decreases in financial metrics are year-over-year. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals or are available only in certain markets.

During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements, except as required by law.

With that, I'd like to turn the call over to Rainer.

[Rainer Blair, executive]

Well, thank you, John, and good morning, everyone. We appreciate you joining us on the call today. Our team delivered strong third quarter results with revenue, adjusted net earnings per share and cash flow all coming in ahead of our expectations. We were especially pleased with the continued positive momentum in bioprocessing and another exceptional quarter at Cepheid, and we enhanced our long-term competitive advantage with the release of several impactful new innovations across our businesses.

Now we see a bright future ahead for Danaher. The transformation in our portfolio over the last several years has created a focused life sciences and diagnostics leader positioned for higher long-term growth, expanded margins and stronger cash flow. Danaher is purpose-built to help customers solve some of the most important health challenges impacting patients around the world.

Our proven ability to innovate is enabling faster, more accurate diagnoses and helping customers reduce the time and cost needed to sustainably develop and deliver life-changing therapies.

Now the unique combination of our talented team, our differentiated science and technology portfolio and the power of the Danaher Business System positions us well as we seek to maximize value for our customers, our associates and our shareholders.

So with that, let's take a closer look at our third quarter 2024 results. Sales were $5.8 billion in the third quarter and we delivered 0.5% core revenue growth. Geographically, core revenues in developed markets increased low single digits with low single-digit growth in North America and mid-single-digit growth in Western Europe. High-growth markets were down mid-single digits, including a high single-digit decline in China.

Our gross profit margin for the second quarter was 58.7%, and our adjusted operating profit margin of 27.5% was down 10 basis points as accelerated investments in innovation offset the favorable impact of cost savings initiatives. Adjusted diluted net earnings per common share of $1.71 were essentially flat year-over-year, and we generated $1.2 billion of free cash flow in the quarter and $3.8 billion year-to-date, resulting in a year-to-date free cash flow to net income conversion ratio of 135%.

Now let's take a closer look at our results across the portfolio and give you some color on what we're seeing in our end markets today. Core revenue in our Biotechnology segment was flat year-over-year with our bioprocessing business up low single digits and our Discovery and Medical business down high single digits.

In bioprocessing, we were encouraged with the continued positive momentum we saw in the quarter. Notably, orders increased high single digits sequentially, which is the fifth consecutive quarter of sequential order improvement and our book-to-bill ratio improved to approximately 1.0.

Now geographically, we saw improving order trends in developed markets as large customers are returning to more normal ordering patterns. In China, orders and underlying activity levels remain weak, particularly for equipment as customers continue to conserve their capital.

Revenue growth in the quarter was driven by our larger pharma, biopharma and CDMO customers. Production volumes at these customers who are primarily manufacturing monoclonal antibody therapies has continued to grow in line with historical averages. Now we've seen demand at these customers steadily improved throughout the year as they're moving past inventory destocking and anticipate this gradual recovery will continue over the coming quarters.

In contrast, we're not seeing the same level of improvement in underlying performance from our smaller customers. Despite a modest improvement in the funding environment, they continue to rationalize their therapeutic programs and remain cautious with their investments. Now putting this all together, we continue to expect low single-digit core revenue decline in our bioprocessing business for the full year 2024. And this includes an assumption of high single-digit core revenue growth in the fourth quarter.

Now as destocking moves behind us, we're increasingly excited about the long-term opportunities ahead for Cytiva's leading bioprocessing franchise. Monoclonal antibodies, which comprise the majority of our revenues, remain the largest investment area for our customers. We're also seeing accelerated adoption of these therapies and 6 of the top 10 highest revenue-generating drugs today are monoclonal antibodies.

With our comprehensive portfolio, our best-in-class scientific services and innovation focused on increasing yields and enhancing manufacturing efficiencies, we believe we're very well positioned to support our customers today and well into the future.

Now turning to our Life Sciences segment. Core revenue decreased by 2%, in line with our expectations. Core revenue in our Life Sciences instruments businesses collectively declined mid-single digits with market conditions in the third quarter, largely consistent with what we saw in the first half of the year. Ongoing research and lab activity is driving growth in consumables and service, which was more than offset by a decline in capital equipment, particularly in China.

Announced stimulus measures in China have not yet translated into meaningful order activity as customers are still awaiting details on the implementation of these programs. Now in the meantime, many customers are delaying purchasing decisions. Outside of China, our end markets are relatively stable, and we were encouraged to see early signs of improvement in demand among our pharma and biopharma customers, particularly in North America.

Now during the quarter, Beckman Coulter Life Sciences introduced the Cydem VT. Cydem VT is a fully automated, high-throughput cell culture system designed to simplify and accelerate the complex and lengthy process of clone screening and cell line development. Now by harnessing the power of the Cydem VT, researchers can optimize workflows and reduce hands-on time by up to 90%, enabling them to efficiently identify the most promising clones, and improve the success rate of their cell line development projects.

In July, we completed the acquisition of Genedata a leading provider of enterprise and workflow software used in drug discovery and development. Genedata's advanced software solutions automate complex R&D processes enabling biopharma researchers to analyze and interpret samples more quickly. So we're really excited to welcome this innovative team to our Life Science segment.

Now Beckman's Cydem VT and the acquisition of Genedata are both great examples of how we're strengthening our long-term competitive advantage while helping our customers accelerate the drug discovery process.

In our genomics consumables business, core revenue declined low single digits, continuing the trends we saw in the second quarter. In August, IDT expanded its synthetic biology portfolio with the launch of Rapid Genes. These ready-to-use NGS verified clonal genes are cost-effective and offer fast turnaround, allowing pharmaceutical researchers to quickly pursue high throughput experiments such as antibody development. IDT's long history of innovation is one of the key reasons the research community turns the IDT to help advance drug discovery and accelerate the pace of genomic medicine development.

Now moving to our Diagnostics segment. Core revenue increased 5%. Our clinical diagnostics businesses collectively delivered low single-digit core revenue growth. Beckman Coulter Diagnostics was up low single digits, with strong global demand, partially offset by the impact of volume-based procurement in China. Outside of China, recurring revenue was up high single digits, driven by recent new product introductions and installed base expansion.

The Beckman team continued their accelerated cadence of new product innovation this quarter with the release of the DxC 500i integrated chemistry and immunoassay analyzer. Now the DxC 500i is specifically designed to improve efficiency and meet the unique workflow needs of low-volume laboratory customers such as community hospitals. So this highlights Beckman's commitment to serving the entire health care network by providing a comprehensive portfolio of solutions for low, mid- and high throughput core labs.

In Molecular Diagnostics, Cepheid's core revenue increased double digits with broad-based strength across respiratory and nonrespiratory assays. Cepheid's respiratory revenue of approximately $425 million in the quarter exceeded our expectation of $200 million as we saw both higher volumes and a favorable mix of our 4-in-1 test for COVID-19, Flu A, Flu B and RSV. Favorable volume was driven in part by customers purchasing in preparation for the upcoming respiratory season.

Now based on activity in the third quarter and our expectation of a respiratory season with normal severity, we expect respiratory revenue of approximately $1.7 billion for the full year of 2024. Outside of respiratory, increasing menu adoption and system utilization helped drive another quarter of mid-teens growth in Cepheid's core nonrespiratory reagent portfolio, including more than 20% growth in Group A Strep, sexual health and urology assays.

We also saw a strong installed base growth, particularly for our lower throughput systems as customers continue to add GeneXpert instruments in their clinics and alternate care sites. So this expansion out of the hospital allows our customers to improve financial and clinical outcomes by standardizing care across their networks.

I'd like to thank all of you who joined us last month for our Investor Day, where we had the opportunity to showcase our differentiated diagnostics portfolio. During the event, we highlighted how DBS-driven innovation and commercial execution have meaningfully improved the growth and margin profile of our diagnostics franchise over the last several years. We also talked about how we are uniquely positioned for long-term growth opportunities in high-value, high-need areas such as neurodegenerative diseases, infectious diseases and oncology. And if you haven't had the chance to see the replay, I'd encourage you to watch it on our Investor Relations website.

Now let's briefly look ahead at expectations for the fourth quarter and the full year 2024. For the full year 2024, there is no change to our previous guidance and as a reminder, we anticipate a core revenue decline in low single-digit percent range and a full year adjusted operating profit margin of approximately 29%.

In the fourth quarter, we expect core revenue to decline in the low single-digit percent range. Additionally, we expect the fourth quarter adjusted operating profit margin of approximately 30%.

So to wrap up, we're pleased with our better-than-expected third quarter performance and expect the trends we're seeing today to continue into Q4. Our team's commitment to executing and innovating with the Danaher Business System enabled us to deliver strong results while continuing to accelerate growth initiatives across the portfolio.

Our third quarter results also reflect the unique positioning of Danaher today. We have an outstanding group of businesses that serve attractive end markets with favorable long-term secular growth drivers. We're further enhancing our portfolio and competitive advantage with innovation that is helping customers solve some of the most important health challenges impacting patients around the world.

So looking ahead, we believe this powerful combination of our leading portfolio, proven ability to innovate and our team's commitment to executing with the Danaher Business System provides a solid foundation for delivering differentiated long-term financial performance.

And so with that, I'll turn the call back over to John.

[John Bedford, executive]

Thanks, Rainer. That concludes our formal comments. Operator, we're now ready for questions.

[Operator]

[Operator Instructions] We'll take our first question from Tycho Peterson with Jefferies.

[Tycho Peterson, analyst]

I want to probe into the instrument numbers a little bit. Wondering if you can give us instrument growth ex China? And then just maybe talk a little bit about where it's worse and where it's getting better, whether it's slow, mass spec, lab automation, microscopy and any leading indicators of funnel dynamics that make you feel better coming out of the quarter on the instrument side?

[Matt McGrew, executive]

Yes, Tycho, it's Matt. I'll give you the kind of the number on what it is. It's probably low to mid-single digit ex China. And then, Rainer, you want to give color on the -- what we're seeing in the instrument side?

[Rainer Blair, executive]

Sure. No, absolutely. So -- and then, of course, in China, we would say that it's down high single digits. But if you look at the developed markets, let's start with those. The end markets were relatively stable sequentially, but we haven't seen an inflection there yet, although in pharma and in biotech, while it remains soft, we're starting to see some early signs of improvement, especially in North America. On the academic research side, there we see it stable in North America with Europe modestly weaker.

But coming back to China, we're all aware, of course, of the announced stimulus, but that really hasn't translated into meaningful orders for us as customers continue to wait for those details. So -- and while they're waiting for those details, they tend to also delay perhaps the normal purchasing habits that they might have had. So the stimulus funding has yet to pick up here in the third quarter.

[Tycho Peterson, analyst]

Okay. And then a follow-up. I know you don't want to talk about '25 yet. But if we look at kind of the run rate for guidance on life sciences that you're giving us for the fourth quarter, the street is at 6% next year on Life Sciences. Is that realistic kind of given the run rate you're laying out for the fourth quarter? And then anything you can say on China buyout process for next year, we've seen some of your peers talk down numbers as well?

[Rainer Blair, executive]

Tycho, we're still looking here to see how the fourth quarter plays out and to see whether we can see a pickup in the stimulus, particularly in China, while we do expect the developed markets to be stable along the lines that I just discussed for Q3. So we're looking to see how China's stimulus plays out here in Q4 before we can get to 2025 numbers. Now as it relates to bioprocessing, we continue to see there a low activity level, albeit stable but at a lower level, and we expect that to take more time to play out here in the near term.

[Matt McGrew, executive]

Yes. Maybe just to kind of follow up. I think the comment on the China stimulus is for tools, Tycho, right, just kind of what we're seeing there for '25 overall -- so that's kind of a '25 overall for Danaher for tools. But for by-processing for '25, I think we've kind of talked about a gradual recovery here in '24, and that's pretty well played out like we thought. Like Rainer said, we do need to see sort of how Q4 plays out, but -- before we kind of give anything for '25.

But that said, the Q4 exit rate of high single digit is an important kind of building block for us as we build backlog and visibility heading into 2025. But given what we've seen here through Q3, I think we're going to see a gradual recovery continue into '25.

[Tycho Peterson, analyst]

Okay. And then on the Life Science, the guidance, fourth quarter down low single digit, but the street next year is up 6%. I was trying to also reconcile whether that step-up is reasonable?

[Matt McGrew, executive]

Yes. I mean I think the biggest factor there for as we look to next year will be what happens with the China stimulus for life sciences.

[Operator]

We'll take our next question from Michael Ryskin with Bank of America.

[Michael Ryskin, analyst]

I actually want to just follow up on exactly your last point there on bioprocess sort of exit rate and how to think about 2025 and just how are you feeling about that market development, the gradual recovery, you talked about, I think, 5 consecutive quarters of order growth there. In the last couple of quarters, you've had high single-digit order growth. Revenues for Bioprocess have done well this year as well, but they've lagged the growth levels. So it seems like there's a little bit of a lag in terms of the orders translating to revenue, which you would expect, obviously.

Do you think that lag is closing? Do you think you were getting closer as we hit 4Q? You talked about high single-digit by process where you're going to start to see some of that order growth we've seen over the last quarter -- couple of quarters start to translate and translate into next year?

[Matt McGrew, executive]

Yes. I mean I think it's a perfect frame. I mean you think about exiting the year at high single digits, but you kind of take a step back and you look at from a core growth perspective in 2024, we're going to be down low single digits. And so as you sort of think about where we kind of exit the totality of '24 with that gradual sort of kind of recovery in mind as we had '25, I think that's kind of the way that we're thinking about it from a perspective of what revenue we'll do next year based on the fact that the order trajectory has gotten better over the last 5 quarters.

But like I said, I mean it would be great for us to see Q4 here before we go. But I do think going down low single digits this year in revenue, be positive next year, we believe. But let's see where the trajectory goes here given the fact that I do believe this is going to kind of be a continuation of what we saw in '24, which is a pretty gradual recovery, very encouraging, though. So we're very happy with where we are.

[Michael Ryskin, analyst]

Okay. All right. And then a follow-up. I want to ask on Cepheid a couple of quick questions, if I can. One is you talked about timing of some purchasing of the kits in the quarter. Any chance you could quantify that? I know you did 425 in respiratory versus the 200 guide. Do you think that 225 was timing or maybe was some of that organic beat and some of it was timing. Just trying to get a sense of how much pull forward that was from the fourth quarter?

And in the press release, you also specifically called out, Cepheid gaining market share in molecular testing. If you could expand on that? Where are you gaining share in terms of customer or geographically? Any specifics there?

[Matt McGrew, executive]

Yes. I mean, Mike, it's a little hard to parse out to the dollar, how much of the beat was related to pull forward versus just sort of better than we thought. I think probably anecdotally from what we heard from customers, I would say that we do believe that there was a good portion of that was probably due to wanting to make sure that they had kind of the security of supply heading into the fourth quarter, which is not a huge surprise, I guess. But as we sort of look forward to the fourth quarter then, we did take that into account as we thought about what we might see here in the fourth quarter. So I'd say a significant portion of the beat was probably related to that.

As far as market shares go, I think I'd probably put it in 2 categories. I'd probably say, one, it's largely in the U.S., though that's not an absolute statement, I would say largely in the U.S., as you know, we are entirely in sort of hospitals as well as near point of care. We've been doing very, very well with IDNs as we've expanded beyond their core hospitals into other point-of-care settings closer to the patient. That has continued here in the quarter, and I expect that, that would continue as well, again, again, with this -- the installed base that we've been able to drive.

[Operator]

We'll move next to Doug Schenkel with Wolfe Research.

[Douglas Schenkel, analyst]

I guess a couple of quick follow-ups. There's been a lot of questions that kind of dance around the 2025 question, which I'm sure you appreciate. When I look at numbers, the street is looking for 8% core growth with bioprocessing growing double digits and Life Sciences growing 7%. You haven't said anything about anything resembling a snapback. Respiratory comps are going to be tough. VBC seems to be picking up in China, stimulus activity follow-through seems unclear. And then just knowing you guys, you tend to be conservative. So cutting to the chase, am I missing anything? And should the street be modeling things at these levels, recognizing you still want to see another quarter? But as we sit here today, the numbers look as mid to high to me. Am I missing anything?

[Rainer Blair, executive]

Well, I don't think you're missing much here. If we just take a look real quick on how we're thinking about 2025, it's important to know that we need to see how Q4 plays out here. I'll come back to that in a minute. But there's still a couple of important variables in Q4 that's going to shape the next year and those relate to really the trajectory of the order book in bioprocessing. It's so important. So certainly, the high single-digit core growth that we expect in bioprocessing for the fourth quarter is fully supported by backlog and what we expect in orders.

But we also want to see more deeply into 2025 by seeing that orders momentum here continue into Q4. So that's going to be key here for understanding how the second half of 2025 plays out in bioprocessing. As it relates to respiratory for Cepheid, and other key variable here as we just talked about, there's been some purchasing ahead here in Q3. And based on what we saw in the Southern Hemisphere, we do expect the Northern Hemisphere to have a more normal respiratory season. And as you know, that straddles -- the first respiratory season of the year straddles Q4 and Q1.

And then lastly, and this is important for life sciences but also more generally, we need to see how this China stimulus plays out in 2025. And we'd like to see some indicators of that accelerating here in Q4 to date, we've not really seen anything meaningful in that regard. So we're going to put numbers all around us here and then update you in January.

[Douglas Schenkel, analyst]

Okay. Super helpful, Rainer. And I guess another follow-up on just I mean essentially trying to get at the question of the utility of the book-to-bill metric. Like if we look at book-to-bill from Q3 of last year and this year and assume that bioprocessing accounts for roughly 85% of biotech sales, it seems like orders were up over 20% year-over-year. So I'm not sure if that math is right, that would be one question.

But if it is, I'm just wondering how important is that as we think about the outlook for a return to robust bioprocessing growth because I think there's some that are concluding that it's taking longer to convert. And I think there's others that are assuming it's converting much more quickly than it used to. I guess we're just trying to get at how useful this metric is, especially keeping in mind this is largely a consumable business at this point.

[Matt McGrew, executive]

Yes. I mean, I think we've talked in the past about book-to-bill being -- it's an interesting number and can be helpful in certain businesses. But traditionally or historically, we have not really used book-to-bill to kind of run this business for the exact reasons you said, lots of consumables and the timing of when the shipments hit. So I think from our perspective, book-to-bill is not something we spend a lot of time thinking about, but we do think about the orders.

And as you said, the orders here in the quarter were north of 20%. Now that is off of a very easy comp. So I think we need to have a little bit of restraint on what that means. But 5 quarters of sequential order growth is important. I think it's also -- what gave me a lot of encouragement in this quarter was, typically, we do see some seasonality where we go down from Q2 to Q3. We did not see that in this environment, I was encouraged by that, that we actually went up again sequentially.

And so I sort of look at everything and think about my order growth rate, the percentages, even though they're off low numbers, that's important. The fact that we've had 5 sequential quarters in a row, coming off of where we've been on the destocking, I think that's an important factor. So yes, to your point, I'm not sure book-to-bill is super critical for us. But maybe triangulating that with those other 2 factors, I really do think we're really happy with the trajectory of what we've seen in 2024 and what that means heading into 2025. But again, I think we're -- we've seen a pretty gradual buildup here in revenue and in orders, and I suspect that, that continues.

[Operator]

We will take our next question from Vijay Kumar with Evercore ISI.

[Vijay Kumar, analyst]

I guess, one, I want to ask on genomics here, low singles, maybe in the past, you spoke about sequencing versus gene editing/writing. What were trends between those 2 segments? And I think this Rapid Gene that you mentioned, maybe talk about what Rapid Gene is and would you expect some share gains here due to launch of this product?

[Rainer Blair, executive]

Sure, Vijay. We -- on the gene reading side of the house, we do still see the market's softer as particularly in the smaller customer emerging biotech segment, we see less activity. While the funding improved, those customers are still prioritizing their project quite a bit. And so we're seeing a bit less consumption in that area. Now on gene editing, of course, that's a different story where we see a great deal of CRISPR and guide RNA and other types of solutions doing very well.

Having said that and coming back to our new product launch here with Rapid Genes, we're very excited about that. This will offer whole genes to our customers at a quality and a turnaround time, which is highly differentiated in the market. We expect that over time here to provide us some tailwinds. So we're very pleased here with how IDT is performing in this environment.

[Vijay Kumar, analyst]

Understood. And maybe, Matt, one for you. Your Q4 operating margin assumption, it came down a tad versus sub prior. I think we're looking at low 30s exit rate. Is there some timing of expenses or anything change on margin assumption? And if it is, any change in investments and implications here as we look at incremental margins for fiscal '25?

[Matt McGrew, executive]

Yes. I mean our full year margins didn't change, approximately 29%, Q4 will be approximately 30%. I mean I think it's probably a function of a couple of things. One, we're going to have -- we anticipate at least lower revenue in respiratory in Q4. Obviously, that has some margin implications to it. I think we did have a little bit of sort of timing, a little bit better bioprocessing in Q3 than we thought and probably some of that might be a little bit of timing related as well sort of impacting Q4 margins.

And as you said, we've had a pretty good year here. And as we head into the fourth quarter, we're thinking about the cost structure, thinking about the investments that we want to make in the business. And we're picking an opportunity to make sure that we do some of those smartly here in the quarter. And I think you sort of add it all up and you kind of come up with that adjusted operating margin in the 30s sort of holding the full year here as we head into the end of the year.

[Vijay Kumar, analyst]

I'm sorry, the incremental margin implications for fiscal '25, should the fall should be in the 35% to 40% range?

[Matt McGrew, executive]

Well, I mean, it's going to depend on volume, I think, Vijay, but like we've kind of talked about from a margin perspective that is this business when it is operating sort of in a normal environment, the low 30s are where it should be. So I mean, '25 we'll sort of update you that. In January when we get there, but that will be a function of volume and mix, depending on where it comes from, it will be different. So we'll have to wait until we get a little bit further to give you that, but that's sort of how I'm thinking about '25.

[Operator]

We'll take our next question from Scott Davis with Melius Research.

[Scott Davis, analyst]

You guys mentioned again this quarter that the smaller customers and bioprocessing not coming back as fast. At what point does it become such a small piece of the business that maybe we stop having that color or it's less material? Or maybe a different way to ask the question is what percent of revenues is it now where it's kind of large versus small customers?

[Matt McGrew, executive]

Yes. I mean the larger versus small roughly, Scott, is kind of 75% or larger and 25% or smaller and I think we give the color primarily because those smaller customers have a little bit of a different dynamic than the larger customers. Larger customers typically have on market or later Phase III trial kind of exposures whereas the smaller customers tend to be earlier stage, probably a little bit more related to, in some instances, the cell and gene therapies of the world.

So little bit different. They act differently in the funding environment as well. So I think it's -- we're just trying to kind of give color as to what we're seeing there, where we are seeing an improvement in the funding environment. It's not necessarily working its way through into orders and revenue at this point. And so just to kind of give a little bit of color.

But to your point, I think, is most of our customers are the larger customers with stuff that is on market. When I look back at what has caused all the pain over the last kind of 2 years in this business, it was destocking at those customers. And I believe that is largely behind us. And so that's why I think it's really encouraging as we stand here and look forward, though the recovery has been gradual. It has happened. It's happened at the largest customers. It gives me a lot of faith that the long-term outlook of this business still is the high single digits. When we get there, kind of a little -- a bit of a TBD, but I think that's the reason we sort of want to give a little bit of color on both of them.

[Scott Davis, analyst]

Okay. That makes sense, Matt. And guys, we didn't talk about the buyback or M&A or kind of your funnel or nothing mentioned in prepared remarks. Any update there as it relates to your confidence or size or any metrics around the funnel would be helpful?

[Matt McGrew, executive]

Yes. I'll just touch real quick on the buyback and maybe Rainer can give some color on the funnel -- the M&A funnel. But I mean the buyback, we -- I think if you see -- we did complete it technically, that buyback was straddled both Q2 and Q3. So if you see something in the queue, that's what it was related to, just so everybody is kind of clear, it was not a new issuance, it was the final pieces, if you will, of the buyback that we talked about in Q2.

[Rainer Blair, executive]

Thanks, Matt. And as it relates to the M&A environment, Scott, as we do every day, we were out there cultivating across all of our segments. And we're fairly active there. Our funnels are pretty dynamic. It's fair to say that while the environment though is improving, valuations are still elevated. And so we feel great about our positioning, both in terms of the assets that are attractive out there and of course, our balance sheet, but we're going to maintain our discipline with our deals needing to meet. Our trifecta of attractive end market, attractive company and then, of course, the valuation framework, the model has to work as well. So active, but we still see that the valuations are elevated.

[Operator]

We'll take our next question from Puneet Souda with Leerink Partners.

[Puneet Souda, analyst]

So specifically on China, just following up on a few things. What's the right sort of jump off point for China for -- as we think about 2025, just given the uncertainties here in the market and the backdrop of the stimulus? And also wondering if you can elaborate a bit on the China value-based pricing? How much of an impact are you baking there?

And just lastly, on China, how much is local bioprocess competition important in this market? And does that change your view for the long-term growth of the worldwide bioprocess or biotech segment long-term growth. Just now that local competition has emerged and is being utilized more in some of those local labs.

[Matt McGrew, executive]

Maybe to start, because I think your first question, your third question sort of wrapped around China for next year in bioprocessing. Maybe I'll let Rainer take that. But just EVP, just to remind everybody, we sort of assumed that it was going to be kind of $150 million impact over 3 years, really starting this year as we ramp up. Our assumptions initially were sort of that, that would be linear over the next 3 years. We are starting to see a little bit more activity in China around VBP here at the end of this year.

So I think we'll have a better sense of what that linear looks like after we get through the next couple of months where it does look like the activity is sort of ramping up. So I still think the number is a good number, but how that rolls out and plays out will sort of be determined in the next couple of weeks.

[Rainer Blair, executive]

As it relates to the JLP, Puneet, really, I think we need to view China as stable and sort of bumping along the bottom, and we don't expect to change in that -- in the short term as we go through and think about 2025 unless we see a material change in the execution and rollout of a stimulus program in China. So we expect China to continue to develop as it has been here for most of the year in 2024. Now as it relates to your question on local competition, certainly, there's local competition out there.

But we have to be clear that particularly in biotech, there are many companies simply struggling to survive and they're buying essentially the least expensive solution that they can to make it to the end of the month. And it's just going to have to be good enough. So that's sort of one section of the market.

Then there's another segment that really is targeting the international sale of their therapeutic molecules, and they tend to want to have solutions from multinational companies, first and foremost, from ourselves here and Cytiva in order to ensure that regulators around the world are comfortable with the inputs that are required to make these incredibly effective drugs.

So yes, there's local competition. We would see it more on the margin, especially as it relates to local molecules.

[Operator]

We'll take our next question from Dan Leonard with UBS.

[Daniel Leonard, analyst]

I wanted to circle back to the trends in Life Science instruments and equipment specifically because I think you do have some consumables in that instrument reporting. Can you elaborate a bit further on what the equipment trends were in the quarter from a growth perspective?

[Rainer Blair, executive]

So just to talk about the quarter more generally. The market conditions in third quarter were essentially consistent with what we saw in the first half of '24 and capital equipment spending continued to be constrained and to the last question, particularly in China. Now in contrast to the equipment, constrained environment, consumables and service grew in the quarter as labs and research facilities and institutions activity has started to stabilize. So we do see equipment being constrained, but consumables are starting to move.

[Daniel Leonard, analyst]

And then a quick follow-up, Rainer. Could you comment on the performance at Abcam? It seems like versus our numbers, the run rate there is improving. I'm not sure if that's the correct read or if it's just rounding or if there's other M&A into that revenue mix?

[Rainer Blair, executive]

There's no other M&A in that revenue mix. But of course, we're working very hard to drive our hypothesis around Abcam. And right now, the focus is on transitioning into Danaher, of course, and the team is making great progress with that. They're implementing -- actually pulling on our DBS capabilities to drive those growth accelerators. And of course, improve the cost positioning that we've talked about. So we feel very good about where we are with Abcam. And long term, we absolutely believe that this meets our expectations, both in terms of growth and the bottom line.

[Operator]

And we will take our final question from Jack Meehan with Nephron Research.

[Jack Meehan, analyst]

I wanted to ask about diagnostics in the China region. To start, for Matt, can you just check my math is, can you remind me, is this like 15% of diagnostic sales? And I was trying to back into how Beckman might have done in the quarter in the region? It could have been to the tune of down 20% or so? And then for Rainer, it would just be great to hear about your thoughts on regional dynamics in Diagnostics. Is this all kind of price impact or any change in kind of share shift?

[Matt McGrew, executive]

Yes. So diagnostics, the total revenue for China Diagnostics, I think you're in the ballpark on that. As far as what China was -- from China Diagnostics perspective in the quarter, I don't think it would have been down that high, Jack, probably it was down in overall diagnostics, which most of that's going to be Beckman. That was kind of down low double digits. So I think that's probably a more -- a better place to anchor, but I think your total number is probably pretty close to right, as far as percent of sales.

[Rainer Blair, executive]

We saw across the world here really with one exception, strong performance in all of our clinical diagnostic businesses. And then of course, you heard from Matt around Cepheid that we believe to be taking share there at -- really at all levels. But coming back to our clinical diagnostic businesses, we saw a high single-digit recurring revenue growth in North America and in Europe.

On the other hand, we come back to China. In China, we see impact of the volume-based procurement, which is what brings us down. We also had in Beckman Coulter in particular, a high hardware sell-out comp last year as we were burning down some backlog. But we're very pleased with how our clinical diagnostics businesses continue to develop, continue to take share and volume-based procurement is sort of the topic right now for diagnostics in China.

[Operator]

Thank you, and this will conclude our Q&A session. I'll turn the call for John for closing remarks.

[John Bedford, executive]

Thank you, everybody, for joining us today. We'll be around for follow-ups all day rest of the week. Thank you.

[Operator]

Thank you. And this does conclude today's program. Thank you for your participation. You may disconnect at any time.